Oncotype portfolio of genomic tests for earlier cancer detection and cancer treatment.

Ended Awarded Last action

Contract number
HT001423F0136
Awardee
Awarding agency
Obligated
$145,066

Award facts

Contract value 100% obligated
$145,066.32 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
NAICS code
621511 Medical Laboratories
PSC
Q301 Reference Laboratory Testing
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Bethesda, MD 20889, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Health Agency awarded a $145,066 firm fixed price blanket purchase agreement call contract to Genomic Health, Inc., a division of Exact Sciences Corporation, to deliver its Oncotype Portfolio of genomic tests for earlier cancer detection and cancer treatment. The testing portfolio aims to support the Defense Health Agency's efforts to advance cancer screening and personalized treatment selection. Performance will occur in Bethesda, Maryland over one year effective September 2023. No subcontractors or set aside designations were identified.

Quick answers

Who was awarded contract HT001423F0136?

HT001423F0136 was awarded to Genomic Health, Inc. by Defense Health Agency (Department of Defense) on September 8, 2023.

How much is contract HT001423F0136 worth?

The government has obligated $145,066 on HT001423F0136.

Is contract HT001423F0136 an order under another contract?

Yes. HT001423F0136 is a BPA call under HT001421A0031, a blanket purchase agreement.

Was contract HT001423F0136 competed?

The extent of competition for HT001423F0136 was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award